BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35587163)

  • 1. The integrated stress response in the induction of mutant KRAS lung carcinogenesis: Mechanistic insights and therapeutic implications.
    Koromilas AE
    Bioessays; 2022 Aug; 44(8):e2200026. PubMed ID: 35587163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer.
    Ghaddar N; Wang S; Woodvine B; Krishnamoorthy J; van Hoef V; Darini C; Kazimierczak U; Ah-Son N; Popper H; Johnson M; Officer L; Teodósio A; Broggini M; Mann KK; Hatzoglou M; Topisirovic I; Larsson O; Le Quesne J; Koromilas AE
    Nat Commun; 2021 Jul; 12(1):4651. PubMed ID: 34330898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitor of Differentiation-1 Sustains Mutant
    Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
    Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).
    Wang IC; Ustiyan V; Zhang Y; Cai Y; Kalin TV; Kalinichenko VV
    Oncogene; 2014 Nov; 33(46):5391-6. PubMed ID: 24213573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YTHDF1 Promotes Cyclin B1 Translation through m
    Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. eIF4E S209 phosphorylation licenses myc- and stress-driven oncogenesis.
    Ruan H; Li X; Xu X; Leibowitz BJ; Tong J; Chen L; Ao L; Xing W; Luo J; Yu Y; Schoen RE; Sonenberg N; Lu X; Zhang L; Yu J
    Elife; 2020 Nov; 9():. PubMed ID: 33135632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS
    Kyriakopoulos G; Katopodi V; Skeparnias I; Kaliatsi EG; Grafanaki K; Stathopoulos C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.
    Hu K; Li K; Lv J; Feng J; Chen J; Wu H; Cheng F; Jiang W; Wang J; Pei H; Chiao PJ; Cai Z; Chen Y; Liu M; Pang X
    J Clin Invest; 2020 Apr; 130(4):1752-1766. PubMed ID: 31874110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The integrated stress response remodels the microtubule-organizing center to clear unfolded proteins following proteotoxic stress.
    Hurwitz B; Guzzi N; Gola A; Fiore VF; Sendoel A; Nikolova M; Barrows D; Carroll TS; Pasolli HA; Fuchs E
    Elife; 2022 Jun; 11():. PubMed ID: 35758650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.
    Baek KH; Bhang D; Zaslavsky A; Wang LC; Vachani A; Kim CF; Albelda SM; Evan GI; Ryeom S
    J Clin Invest; 2013 Oct; 123(10):4375-89. PubMed ID: 24018559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma.
    Li Z; Zhuang X; Pan CH; Yan Y; Thummalapalli R; Hallin J; Torborg S; Singhal A; Chang JC; Manchado E; Dow LE; Yaeger R; Christensen JG; Lowe SW; Rudin CM; Joost S; Tammela T
    Cancer Discov; 2024 Feb; 14(2):308-325. PubMed ID: 37931288
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Wang X; Min S; Liu H; Wu N; Liu X; Wang T; Li W; Shen Y; Wang H; Qian Z; Xu H; Zhao C; Chen Y
    EMBO Mol Med; 2019 Jun; 11(6):. PubMed ID: 31036704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.
    Okudela K; Yazawa T; Woo T; Sakaeda M; Ishii J; Mitsui H; Shimoyamada H; Sato H; Tajiri M; Ogawa N; Masuda M; Takahashi T; Sugimura H; Kitamura H
    Am J Pathol; 2009 Aug; 175(2):867-81. PubMed ID: 19608870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
    Green S; Trejo CL; McMahon M
    Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor progression and chromatin landscape of lung cancer are regulated by the lineage factor GATA6.
    Arnal-Estapé A; Cai WL; Albert AE; Zhao M; Stevens LE; López-Giráldez F; Patel KD; Tyagi S; Schmitt EM; Westbrook TF; Nguyen DX
    Oncogene; 2020 Apr; 39(18):3726-3737. PubMed ID: 32157212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells.
    Unni AM; Harbourne B; Oh MH; Wild S; Ferrarone JR; Lockwood WW; Varmus H
    Elife; 2018 Nov; 7():. PubMed ID: 30475204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
    Ambrogio C; Köhler J; Zhou ZW; Wang H; Paranal R; Li J; Capelletti M; Caffarra C; Li S; Lv Q; Gondi S; Hunter JC; Lu J; Chiarle R; Santamaría D; Westover KD; Jänne PA
    Cell; 2018 Feb; 172(4):857-868.e15. PubMed ID: 29336889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.
    Nokin MJ; Darbo E; Travert C; Drogat B; Lacouture A; San José S; Cabrera N; Turcq B; Prouzet-Mauleon V; Falcone M; Villanueva A; Wang H; Herfs M; Mosteiro M; Jänne PA; Pujol JL; Maraver A; Barbacid M; Nadal E; Santamaría D; Ambrogio C
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32759499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis.
    Jiang L; Wang R; Fang L; Ge X; Chen L; Zhou M; Zhou Y; Xiong W; Hu Y; Tang X; Li G; Li Z
    Theranostics; 2019; 9(9):2460-2474. PubMed ID: 31131047
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting KRAS mutant lung cancer: light at the end of the tunnel.
    Drosten M; Barbacid M
    Mol Oncol; 2022 Mar; 16(5):1057-1071. PubMed ID: 34951114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.